- Home
- FHTX vs HUMA Comparison
FHTX vs HUMA Comparison
Compare FHTX & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FHTX | HUMA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.4M | 165.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FHTX | HUMA |
|---|---|---|
| Price | $2.10 | $0.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $6.00 | $1.85 |
| AVG Volume (30 Days) | 987.0K | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.32 | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,909,000.00 | $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | $15.98 | $518.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $1.79 | $0.47 |
| 52 Week High | $7.61 | $1.90 |
Technical Indicators
Market Signals| Indicator | FHTX | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 16.48 | 27.19 |
| Support Level | N/A | N/A |
| Resistance Level | $5.35 | $0.75 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 12.43 | 6.40 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.